La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Central Pharmaceutical No3 Croissance future

Future contrôle des critères 0/6

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	16.8%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

HNX:DP3 - Estimations futures des analystes et données financières antérieures (VND Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2024	395,207	119,189	99,840	100,251	N/A
3/31/2024	393,686	123,070	117,462	121,754	N/A
12/31/2023	409,731	125,263	144,292	148,790	N/A
9/30/2023	437,247	115,462	133,389	133,972	N/A
6/30/2023	454,355	112,885	130,680	126,737	N/A
3/31/2023	478,070	110,902	88,590	102,680	N/A
12/31/2022	485,074	108,824	84,126	99,215	N/A
9/30/2022	466,732	100,148	72,858	87,831	N/A
6/30/2022	439,432	97,217	-11,863	3,187	N/A
3/31/2022	410,106	98,580	42,407	44,059	N/A
12/31/2021	381,077	94,305	25,862	26,308	N/A
9/30/2021	377,540	100,467	38,758	106,785	N/A
6/30/2021	384,213	106,614	52,013	94,251	N/A
3/31/2021	381,982	109,143	27,967	96,148	N/A
12/31/2020	395,721	114,061	54,119	122,361	N/A
9/30/2020	390,308	79,192	50,791	51,233	N/A
6/30/2020	414,641	84,092	-22,300	-22,425	N/A
3/31/2020	417,252	84,281	63,957	33,175	N/A
12/31/2019	411,433	82,804	29,641	29,685	N/A
9/30/2019	422,776	78,546	5,837	6,318	N/A
6/30/2019	433,396	78,929	4,337	4,835	N/A
3/31/2019	451,125	82,658	20,116	68,446	N/A
12/31/2018	471,503	80,071	63,044	80,522	N/A
9/30/2018	439,461	92,382	17,171	34,286	N/A
12/31/2017	328,141	38,335	N/A	37,791	N/A
9/30/2017	321,383	30,929	N/A	82,511	N/A
12/31/2016	237,634	22,503	N/A	15,532	N/A
9/30/2016	224,750	20,748	N/A	17,517	N/A
12/31/2015	212,098	16,220	N/A	22,531	N/A
9/30/2015	198,874	8,695	N/A	3,001	N/A
6/30/2015	191,613	7,996	N/A	9,906	N/A
3/31/2015	187,955	9,843	N/A	1,852	N/A
12/31/2014	184,296	11,690	N/A	-6,203	N/A
1/1/2014	151,880	7,943	N/A	-1,215	N/A

Central Pharmaceutical No3 Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Second quarter 2024 earnings released: EPS: ₫1,290 (vs ₫1,470 in 2Q 2023)

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: ₫1,025 (vs ₫1,071 in 1Q 2023)

Full year 2023 earnings released: EPS: ₫5,826 (vs ₫4,808 in FY 2022)

Upcoming dividend of ₫3,000 per share

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: ₫878 (vs ₫758 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₫3,676 (vs ₫1,378 in 2Q 2022)

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 25%

Investor sentiment improves as stock rises 18%

First quarter 2023 earnings released: EPS: ₫2,677 (vs ₫3,011 in 1Q 2022)

Upcoming dividend of ₫8,000 per share at 5.8% yield

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: ₫12,654 (vs ₫10,966 in FY 2021)

No independent directors

Third quarter 2022 earnings released: EPS: ₫1,894 (vs ₫2,638 in 3Q 2021)

Second quarter 2022 earnings released: EPS: ₫3,446 (vs ₫3,610 in 2Q 2021)

First quarter 2022 earnings released: EPS: ₫2,448 (vs ₫1,975 in 1Q 2021)

No independent directors

Upcoming dividend of ₫6,000 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: EPS ₫3,610 (vs ₫3,975 in 2Q 2020)

First quarter 2021 earnings released: EPS ₫1,975 (vs ₫2,521 in 1Q 2020)

First Dividend Is ₫8,000 Per Share

Investor sentiment improved over the past week

New 90-day high: ₫109,700

New 90-day high: ₫87,000

New 90-day high: ₫86,000

New 90-day high: ₫84,000

Third quarter earnings released

New 90-day high: ₫75,200

New 90-day high - ₫74,000

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance